Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 8/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455472 | 1.00 | GRB2 (0.39) | GRB2RENCMA1OPRM1OPRD1 | |
| SCHEMBL29468784 | 0.93 | REN (0.46) | GRB2RENOPRM1OPRD1 | |
| SCHEMBL29375930 | 0.88 | OPRM1 (0.43) | GRB2RENOPRM1OPRD1 | |
| SCHEMBL29376028 | 0.88 | OPRM1 (0.43) | GRB2RENOPRM1OPRD1 | |
| SCHEMBL30543475 | 0.87 | GRB2 (0.41) | GRB2CMA1OPRM1OPRD1KMT2A | |
| SCHEMBL30414346 | 0.87 | GRB2 (0.42) | GRB2CMA1OPRM1OPRD1KMT2A | |
| SCHEMBL29468804 | 0.86 | GRB2 (0.41) | GRB2CMA1OPRM1OPRD1KMT2A | |
| SCHEMBL29468889 | 0.85 | GRB2 (0.42) | GRB2CMA1OPRM1OPRD1KMT2A | |
| SCHEMBL31140016 | 0.85 | CAPN1 (0.41) | GRB2RENOPRM1OPRD1 | |
| SCHEMBL30013216 | 0.85 | CAPN1 (0.41) | GRB2RENOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| EP-4436991-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Sun Pharmaceutical Industries Limited (IN) | 2024-10-02 | — | — | EP | disclosed |
| EP-4204440-A1 | GLP-1/GIP DUAL AGONISTS | Sun Pharmaceutical Industries Limited (IN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023089594-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022079639-A1 | GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019410-A1 | PROCESS FOR THE PREPARATION OF TIRZEPATIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | SYK, TREH, QDPR | GRB2 1049/4885REN 4/4885CMA1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.